need more than the quarterly, page-2

Perhaps some conversation will spark a few players.

Just started a list of questions for Denis....perhaps a little wobbly on the wording and research just now but I'm working on it ATM but any input here would help...chuck a few more Questions in for me if you like.

• What percentage of Ropen will be sold overseas, is it a case of having to supply Russia first and foremost, or the highest price wins?
• How any courses have been sold to date?
• Are overseas sales paid for immediately by patients to Solagran or invoiced to a medical institution. It helps for working out Quarterlies.
• Could sales numbers and of all SLA products, even if only invoiced, be noted in each quarterly, including which country received what numbers?
• Who, and how many, are the Russian scientists and Administrators of Solalife, what are their roles, and how much of the 28mill shares go to each?
• Is Solalife the new Solamind with all/some of the holders, and is this issue of shares to compensate them for their losses in Opes Prime? If so then will Solamind be returning any monies back to Solagran they get from litigation.
• If any of the Solalife leaves or becomes unable to perform their full duties or is deceased, what happens to those shares, can we see the full contract before we vote?
• Will these shares be issued in accordance with the Remuneration Plan as of the 2007 AGM, E.G. Shares issued under this Plan are to be issued to Participants in July each year at Market Price.
• The issue of options to Denis and Vagif seem to be double dipping on the agreement from the last AGM, are they being issued above this agreement, or even above what I would call acceptable. is it to compensate for losses as in Solaminds case, if so will monies from litigation be returned to SLA? Perhaps the issue of Options should be valued in July next year.
•